|
|
|
|
|
|
|
|
|
|
Biological: Chimeric monoclonal antibody (TRC105) to CD105
10 mg/kg weekly by intravenous administration on Days 1, 8, 15 and 22 of each 28-day cycle
Other Names:
- TRC105
- NSC#754227
Tuesday, June 28, 2011
phase 11 - Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma - Full Text View - ClinicalTrials.gov (not yet recruiting)
Biological: Chimeric monoclonal antibody (TRC105) to CD105
Subscribe to:
Post Comments
(
Atom
)
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.